Astellas Pharma

Astellas Pharma

Dedicated to the development of high-quality peer-reviewed publications covering Astellas products that are compliant with applicable regulations and guidance.

  • Edit
Get premium to view all results
DateInvestorsAmountRound
N/A

€0.0

round

N/A

Grant
Total Funding000k

Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
JPY2022202320242025202620272028
Revenues0000000000000000000000000000
% growth4 %17 %6 %19 %2 %4 %(7 %)
EBITDA0000000000000000000000000000
% EBITDA margin17 %16 %12 %13 %22 %25 %26 %
Profit0000000000000000000000000000
% profit margin10 %7 %1 %3 %7 %10 %10 %
EV0000000000000000000000000000
EV / revenue00.0x00.0x00.0x00.0x00.0x00.0x00.0x
EV / EBITDA00.0x00.0x00.0x00.0x00.0x00.0x00.0x
R&D budget0000000000000000000000000000
R&D % of revenue19 %18 %18 %17 %---

Source: Company filings or news article, Equity research estimates

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo
Investments analysisEdit

Investments by Astellas Pharma

Edit
Ganymed Pharmaceuticals
ACQUISITION by Astellas Pharma Oct 2016
Iveric Bio (Formerly Ophthotech)
ACQUISITION by Astellas Pharma Apr 2023
Nanotherapeutics
ACQUISITION by Astellas Pharma Apr 2020
Audentes Therapeutics
ACQUISITION by Astellas Pharma Dec 2019
Agensys
ACQUISITION by Astellas Pharma Dec 2007
FibroGen
exited
Ogeda
ACQUISITION by Astellas Pharma Apr 2017
Universal Cells
ACQUISITION by Astellas Pharma Feb 2018
View 45 more